If you have considered hormone replacement therapy (HRT), you may have heard conflicting information about its relationship with breast cancer. You may have been told that HRT causes breast cancer, that every form carries the same risk, or that anyone with a family history should avoid hormone therapy altogether. Decades of headlines have made it difficult to separate established evidence from outdated or oversimplified assumptions.
For Breast Cancer Awareness Month, Genesis Lifestyle Medicine is taking a closer look at HRT and breast cancer. Here, we separate the most common myths from the facts so you can better understand the research and have an informed conversation with your provider.
Fiction: HRT inevitably causes breast cancer
Fact: The relationship between HRT and breast cancer is complex.
Hormone replacement therapy, also called menopausal hormone therapy, replaces hormones that decline as you approach and enter menopause. It may be used to help manage symptoms such as hot flashes, night sweats, sleep disturbances, and vaginal symptoms.
Concerns about HRT and breast cancer became especially prominent following early findings from the Women's Health Initiative (WHI) in 2002. However, subsequent research and longer follow-up have provided considerably more context.
A 2024 review of the Women's Health Initiative randomized trials examined decades of evidence from the WHI. Researchers concluded that menopausal hormone therapy may be appropriate for managing menopausal symptoms in appropriately selected women in early menopause who do not have contraindications.
According to the Breast Cancer Research Foundation (BCRF), assessing breast cancer risk in relation to HRT requires considering factors such as your age, the type and dose of hormones, how long you use them, when treatment begins, and your breast cancer history. In other words, HRT and breast cancer cannot accurately be reduced to a simple cause-and-effect statement.
Fiction: All forms of HRT carry the same risk
Fact: The hormones used in your treatment determine the risk.
There are two primary forms of systemic menopausal HRT: estrogen-only therapy and combination therapy containing estrogen plus a progestogen.
Estrogen-only therapy is generally used if you have undergone a hysterectomy. If you still have your uterus, estrogen is combined with a progestogen because taking systemic estrogen without adequate endometrial protection can increase the risk of endometrial cancer.
Importantly, breast cancer findings have differed between these therapies. Long-term WHI findings found that longer use of combination HRT was associated with increased breast cancer risk, although the absolute risk was low compared with placebo. In the WHI population with prior hysterectomy, estrogen-only therapy was associated with a lower incidence of breast cancer.
These do not mean estrogen prevents breast cancer. However, it is inaccurate to treat every formulation as having an identical risk profile.
Fiction: The original HRT research tells us everything we need to know today
Fact: More than two decades of additional research have changed how the original findings are interpreted.
The initial WHI findings had an enormous effect on HRT use. However, the population studied during that study included women ages 50 to 79, and many participants were older or had been through menopause for years before starting hormone therapy.
The 2024 JAMA review revisited the WHI randomized trials with up to 20 years of follow-up. One important conclusion was that outcomes vary according to factors such as age and timing of therapy initiation. Women ages 50 to 59 in WHI follow-up had lower risks associated with hormone therapy than women ages 60 and older. This has contributed to an individualized approach to HRT rather than treating findings from one population as universally applicable.
Research has not shown that the original concerns were simply “wrong.” Instead, continuing research has helped clarify who was studied, what formulations were used, and how individual characteristics can influence the balance between potential benefits and risks.
Fiction: How long you use HRT makes no difference
Fact: Duration can be an important part of your risk assessment.
Breast cancer risk associated with HRT is not necessarily static over time. The WHI follow-up found increasing breast cancer risk with longer use of combination HRT. A large UK study also found higher risks associated with longer use of systemic combination therapy, while past use for less than five years was not associated with increased risk in that particular study.
This is why your HRT plan should not necessarily be viewed as something that is decided once and never reconsidered. Your healthcare provider may periodically evaluate your symptoms, health history, treatment response, and evolving risk factors when determining whether continuing treatment remains appropriate for your goals.
Fiction: If you have had breast cancer, systemic HRT carries the same risks as it does for everyone else
Fact: A personal history of breast cancer changes the discussion.
Current evidence requires considerably greater caution when considering systemic HRT after breast cancer. Systemic HRT is not currently recommended for women with a history of breast cancer. A systematic review and meta-analysis, published in 2022 based on 2021 research, found that systemic HRT was associated with an increased risk of breast cancer recurrence among survivors, particularly those who previously had hormone receptor-positive disease.
Hormone receptor-positive breast cancer is sensitive to hormones such as estrogen and/or progesterone. This is why endocrine therapies used to treat certain breast cancers work by reducing hormone production or interfering with hormonal signaling. If you have previously had breast cancer, your diagnosis, receptor status, history, current medications, symptoms, and risk factors all need to be considered with your oncology teams before using hormone treatments.
Fiction: Vaginal estrogen and systemic HRT are the same thing
Fact: Route of administration and systemic exposure matter.
Systemic HRT circulates throughout your body. Local vaginal estrogen is intended primarily to act on vaginal tissues and typically results in substantially less systemic exposure. This is particularly relevant for breast cancer survivors experiencing symptoms of menopause.
A study presented at the 2025 ASCO Annual Meeting evaluated 18,620 women ages 65 and older with breast cancer, including 800 who used vaginal estrogen. After adjusting for several variables, researchers did not find evidence of worse survival among vaginal estrogen users; the vaginal-estrogen group actually had lower all-cause and breast cancer-specific mortality.
However, this does not prove that vaginal estrogen improves survival. The research was retrospective and observational, and as a conference abstract it has not yet undergone full peer review, so these findings should be considered preliminary. The findings instead add to evidence suggesting that local vaginal estrogen should not automatically be viewed as equivalent to systemic HRT when evaluating risks.
Fiction: Hormone therapy for breast cancer is another form of HRT
Fact: These treatments generally have opposite purposes.
The terminology can be confusing, but hormone replacement therapy and hormone therapy for breast cancer are fundamentally different. HRT supplies hormones to help address symptoms associated with declining hormone levels during menopause. Breast cancer hormone therapy, also called endocrine therapy, aims to reduce hormone production or block hormonal signaling in hormone-sensitive cancer cells.
Examples of endocrine therapies include medications that block estrogen receptors or reduce estrogen production. These may be prescribed to reduce the likelihood of recurrence in people with hormone receptor-positive breast cancer.
Fiction: Modern research means HRT is now considered risk-free
Fact: A more nuanced understanding of HRT does not mean the risks have disappeared.
Starting in 2025, the FDA began approving changes to boxed warnings on menopausal hormone therapy products after reviewing newer evidence and the limitations of earlier interpretations, with label updates continuing to roll out across additional products since then. However, as the American Cancer Society explains, removing certain boxed warnings does not mean previous research was disproven or that HRT is safe for everyone. Instead, modern evidence increasingly supports an individualized assessment of potential benefits and risks.
Your age, menopause symptoms, time since menopause began, whether you have a uterus, the hormones and delivery method being considered, duration, cardiovascular and other health considerations, and personal and family cancer history may all be relevant.
Get the facts about HRT
The conversation around HRT has changed considerably over the past two decades. Rather than viewing hormone therapy as universally safe or dangerous, current evidence supports looking carefully at your individual circumstances.
Genesis Lifestyle Medicine takes a personalized approach to hormone therapy, considering your symptoms, health history, and goals. Join us for our upcoming Breast Cancer Awareness Month webinar to learn more about HRT and breast cancer and get the information you need to have a productive conversation with your healthcare provider.
Have questions about HRT and breast cancer?
Book a ConsultationThis article is provided for educational purposes only and does not constitute medical advice. It is not a substitute for consultation with a qualified healthcare provider. Decisions about hormone replacement therapy should be made individually with your physician, taking into account your personal health history, risk factors, and goals. Genesis Lifestyle Medicine encourages you to discuss any questions about HRT and breast cancer risk with your provider before starting, stopping, or changing any treatment.
Medically reviewed by Dr. Alex Spinoso
Sources
- Women's Health Initiative (WHI)
- 2024 review of the Women's Health Initiative randomized trials (JAMA)
- Breast Cancer Research Foundation (BCRF)
- 2020 UK Study on Combination Therapy (PMC)
- 2021 Systematic Review and Meta-analysis (Springer Link)
- 2025 Journal of Clinical Oncology Study
- American Cancer Society – What to Know About HRT and Cancer Risk
Back to Blog
